Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 20Lymphoid 11Myeloid 7Plasma cell 2Gastrointestinal 2Sarcoma 1Genitourinary 1Classical hematology 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Neoplasms 2Neoplasm Metastasis 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Triple Negative Breast Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Head and Neck Neoplasms 1

Interventions

trametinib 3pertuzumab 3dabrafenib 3Specimen Handling 3Nivolumab 3Bevacizumab 3venetoclax 2palbociclib 2copanlisib 2cobimetinib 2Vemurafenib 2Trastuzumab 2Sunitinib 2Sorafenib 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Leucovorin 2Ipilimumab 2Immunoglobulin G 2HhAntag691 2Fluorouracil 2Disulfides 2Dasatinib 2CTLA-4 Antigen 2Afatinib 2Ado-Trastuzumab Emtansine 22C4 antibody 2vactosertib 1ulixertinib 1trastuzumab biosimilar HLX02 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hematologic Neoplasms × venetoclax × Gastrointestinal × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03082209 2022-12-09

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

AbbVie

Phase 1 Completed
153 enrolled
GastrointestinalLymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡